Healthcare Provider Matches Prior Full-Year Revenue in Just Nine Months
Chicago, Wednesday, 7 October 2026.
Cosmos Health reached $54.3 million in nine-month revenue, matching its full-year 2024 total. Driven by strong American sales momentum, the company expects 2026 revenue to top $90 million.
Record Nine-Month Revenue Announced
Cosmos Health Inc. (NASDAQ: COSM) announced preliminary unaudited revenue of approximately $54.3 million for the nine-month period ending September 30, 2026 [1]. This figure represents a 19% increase compared to the $45.6 million reported in the same period of 2025 [1]. The calculation of this growth rate is derived as 19.079 [1]. Third-quarter 2026 preliminary revenue reached approximately $17.4 million, marking the highest third quarter in company history [1]. This performance exceeds the previous Q3 record of $17.1 million set in 2025 [1]. The company delivered record third-quarter revenue of $17.4 million, up 40% from Q3 2024 [1]. Operational momentum was driven by strong demand across core business segments, including contract manufacturing, pharmaceutical distribution, and proprietary brands [1].
Operational Drivers and Segment Performance
Growth drivers include a record contract manufacturing pipeline at Cana Laboratories exceeding 32.7 million units [1]. The company’s subsidiary, CosmoFarm, achieved record Q2 2026 revenue exceeding $15 million, representing an annualized run-rate of over $60 million [3]. CosmoFarm services a network of over 1,500 pharmacies, with daily-served pharmacies increasing from approximately 100 in 2017 to approximately 360 currently [3]. Management reaffirmed its outlook for full-year 2026 revenue to surpass $90 million [1]. The company expects the fourth quarter of 2026 to be the strongest in its history [1]. This projected full-year revenue represents a significant increase over the 2025 full-year revenue of $65.3 million [1].
Market Reaction and Stock Performance
As of October 6, 2026, the stock is priced at $0.32, with a market capitalization of $32.50 million [2]. On October 7, 2026, Cosmos Health stock traded between a low of $0.31 and a high of $0.35 [5]. Shares are currently priced at $0.32, which is 3.7% above the low and 8.7% below the high for the day [5]. This performance follows a period where shares hit a 52-week low of $0.16 on June 30, 2026 [4]. At that time, the company announced a share repurchase program of up to $5 million [4]. The stock has declined 64.48% year-to-date in 2026 prior to this recent activity [4].
Strategic Outlook and Risk Factors
The company identifies key operational risks including the timing of contract manufacturing conversion into revenue and potential asset-backed financing programs [1]. Investors are advised against relying on forward-looking statements as actual results may differ materially from expectations [1]. Cosmos Health directs stakeholders to their periodic filings available on the SEC website for a comprehensive list of risks [1]. The next earnings release is estimated for November 13, 2026 [2]. Earnings are projected to grow from ($0.21) to $0.07 per share in the coming year [2].